Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery

Caesarean Clinical Trial

Official title:

Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery in Soba Hospital Sudan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01347593
• Other study ID #: ceftizoxime cesarean
• Status: Completed
• Phase: Phase 4
• First received: May 2, 2011
• Last updated: January 16, 2013
• Start date: May 2011
• Est. completion date: August 2011

Study information

• Verified date: January 2013
• Source: University of Khartoum
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ceftizoxime (Cefizox) will reduce post Cesarean delivery febrile morbidity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: August 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 14 Years to 45 Years

Eligibility

Inclusion Criteria:

• Elective Cesarean section

Exclusion Criteria:

• Diabetes severe anaemia allergy

Related Conditions & MeSH terms

• Caesarean

Intervention

Drug:
• ceftizoxime
ceftizoxime (cefizox) injection either after clamping the cord

Locations

Country	Name	City	State
Sudan	Soba Hospital	Khartoum

Sponsors (2)

Lead Sponsor	Collaborator
University of Khartoum	Ministry of Health, Sudan

Country where clinical trial is conducted

Sudan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	reducing post Cesarean section febrile morbidity	reducing infection rate	4 days